Inclusion body myositis (IBM) is an autoimmune myopathy that occurs mainly in people older than 50 years of age. The pathogenesis is not completely understood, but if thought to involve an interplay between inflammatory and degenerative pathways. No specific pharmacological therapy has been proven to be beneficial for sporadic inclusion body myositis. This activity describes the pathophysiology, evaluation, and management of inclusion body myositis and stresses the role of the interprofessional team in the care of affected patients.

**Objectives:**
- Describe the pathophysiology of inclusion body myositis.

- Describe the important steps in the diagnosis of inclusion body myositis.
- Describe the important steps in the management of inclusion body myositis.
- Explain the importance of optimizing coordination amongst the interprofessional team to enhance the delivery of care to patients with inclusion body myositis.